CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial Clinical trials of subcutaneous tirzepatide (SURMOUNT 1, 2 and 3 Download Scientific Diagram CagriSema in Clinical Trials: What Patients Should Know For an adult with type 2 diabetes mellitus who requires substantial weight loss, what are the recommended use, dosing, regulatory approval status, and contraindications of tirzepatide compared with cagrilintide, and what alternative Cagrilintide: What It Is and How It's Being Studied for Weight Loss Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed